Stereotactic Magnetic Resonance Guided Radiation Therapy
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: MRI scans
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests SMART, a type of targeted radiation treatment guided by MRI scans and adjusted during care. It is for adults with cancer who need targeted radiation. The study will check if treatment can be given safely, how well it controls tumors, and whether patients report feeling or doing better.
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Have confirmed cancer that needs stereotactic body radiation therapy, which uses targeted radiation.
- Have a tumor no larger than 7 centimeters.
- Be age 18 or older.
- Be able to care for yourself and be up and about for at least half of your waking hours.
- Be able to understand the study and willing to sign a consent form.
- Meet any other rules for the group studying your cancer site.
Who can't join
- Have had an allergic reaction to gadolinium, a dye given through a vein for MRI scans. This rule does not apply if you will not get the dye.
- Be pregnant.
- Have severe fear of tight spaces or severe anxiety.
- Be unable to have an MRI scan.
- Meet any other exclusion rules for the group studying your cancer site.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details. * Tumor size ≤ 7cm * Age 18 years of older. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) * Ability to understand and the willingness to sign a written informed consent document. * Specific eligibility requirements for each disease site with be covered in each specific cohort. Exclusion Criteria: * Specific exclusion requirements for each disease site with be covered in each specific cohort * History of allergic reactions attributed to gadolinium-based IV contrast. \-- Note: If a patient will not receive contrast, this is not applicable * Pregnant women are excluded from this study. * Severe claustrophobia or anxiety * Participants who cannot undergo an MRI
Study sites (2)
MA
- Brigham & Women's Hospital · Boston, MA 02115Jonathan Leeman, MD · Study contactJonathan Leeman, MD · Principal investigatorMore trials in Boston
- Dana Farber Cancer Institute · Boston, MA 02115Jonathan Leeman, MD · Study contactJonathan Leeman, MD · Principal investigatorMore trials in Boston